Dr. Harris is involved in several ongoing investigations of new therapeutics for the treatment of gastrointestinal malignancies. His main current focus of investigation involves the study of new drugs such as targeted therapy and/or immunotherapy, the study of novel combinations of drugs, or local interventions in combination with experimental drug therapies for the treatment of hepatocellular carcinoma and biliary tract cancers (including cholangiocarcinoma). These trials include Phase I-III trials. Additional areas of focus include data analysis of outcomes after localized or systemic therapy for gastrointestinal malignancies, as well as identification of new treatments for fibrolamellar hepatocellular carcinoma, a rare disease affecting children and young adults.
Gastrointestinal cancers including liver, bile duct, pancreas, colon, rectal, anal, gastric, esophageal, and neuroendocrine tumors.